Novel antifungal agents in clinical trials
Open Access
- 28 June 2021
- journal article
- Published by F1000 Research Ltd in F1000Research
- Vol. 10, 507
- https://doi.org/10.12688/f1000research.28327.1
Abstract
Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics. The significant morbidity and mortality associated with these pathogens bespeaks the urgent need for novel safe and effective therapeutics. This review highlights promising investigational antifungal agents in clinical phases of development: fosmanogepix, ibrexafungerp, rezafungin, encochleated amphotericin B, oteseconazole (VT-1161), VT-1598, PC945, and olorofim. We examine three first-in-class members of three novel antifungal classes, as well as new agents within existing antifungal classes with improved safety and tolerability profiles due to enhanced pharmacokinetic and pharmacodynamic properties.Keywords
Funding Information
- Henry Schueller Foundation
This publication has 80 references indexed in Scilit:
- In Vitro Activity of Manogepix against Multidrug-Resistant and Panresistant Candida auris from the New York OutbreakAntimicrobial Agents and Chemotherapy, 2020
- Non-Aspergillus Hyaline Molds: Emerging Causes of Sino-Pulmonary Fungal Infections and Other Invasive MycosesSeminars in Respiratory and Critical Care Medicine, 2020
- In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017Antimicrobial Agents and Chemotherapy, 2019
- APX001 and Other Gwt1 Inhibitor Prodrugs Are Effective in Experimental Coccidioides immitis PneumoniaAntimicrobial Agents and Chemotherapy, 2019
- In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against CryptococcusAntimicrobial Agents and Chemotherapy, 2018
- In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida aurisAntimicrobial Agents and Chemotherapy, 2018
- The Investigational Agent E1210 Is Effective in Treatment of Experimental Invasive Candidiasis Caused by Resistant Candida albicansAntimicrobial Agents and Chemotherapy, 2015
- Hidden Killers: Human Fungal InfectionsScience Translational Medicine, 2012
- Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular MethodsAntimicrobial Agents and Chemotherapy, 2012
- In Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and MoldsAntimicrobial Agents and Chemotherapy, 2011